Insmed (INSM) Amortization of Deferred Charges (2012 - 2026)
Insmed (INSM) posted quarterly Amortization of Deferred Charges of $1.4 million for Q1 2026, down 24.15% year-over-year from $1.8 million in Q1 2025, and up 132.02% quarter-over-quarter from -$4.3 million in Q4 2025.
Insmed (INSM) Amortization of Deferred Charges (2012 - 2026) Analysis & Trends
Insmed's Amortization of Deferred Charges history runs 15 years deep, the most recent figure standing at $1.4 million for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges fell 24.15% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $84000.0 (down 98.77% YoY), while the FY2025 annual figure was $524000.0, down 92.39% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $1.4 million, up from -$4.3 million in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $2.0 million in Q2 2023, with the low at -$4.3 million in Q4 2025.
- The 5-year median for Amortization of Deferred Charges is $1.7 million (2025), against an average of $1.2 million.
- The sharpest annual moves came in 2023 and 2025: Amortization of Deferred Charges surged 144.09% in 2023, then slumped 346.91% in 2025.
- Insmed's Amortization of Deferred Charges stood at $1.5 million in 2022, then increased by 14.81% to $1.8 million in 2023, then fell by 0.23% to $1.7 million in 2024, then plunged by 346.91% to -$4.3 million in 2025, then surged by 132.02% to $1.4 million in 2026.
- Business Quant data shows INSM's Amortization of Deferred Charges at $1.4 million in Q1 2026, -$4.3 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.43 Mn |
| Jun 30, 2026 | 1.43 Mn |
| Mar 31, 2026 | 1.38 Mn |
| Mar 31, 2026 | 1.38 Mn |
| Dec 31, 2025 | -4.32 Mn |
| Dec 31, 2025 | -4.32 Mn |
| Sep 30, 2025 | 1.34 Mn |
| Sep 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Jun 30, 2025 | 1.68 Mn |
| Mar 31, 2025 | 1.82 Mn |
| Mar 31, 2025 | 1.82 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Sep 30, 2024 | 1.49 Mn |
| Sep 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 1.80 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Mar 31, 2024 | 1.85 Mn |